

NEWS RELEASE

Kuala Lumpur/Singapore, 29 Aug 2025

IHH Healthcare delivers resilient financial performance in Q2 2025

- IHH Healthcare strengthens its healthcare leadership with revenue up 3% to RM6.3 billion.
- On a constant currency basis, revenue and EBITDA grew 18% and 11% respectively.
- Declared interim dividend of 5 sens for FY2025, up from 4.5 sens last year

“We reported resilient financial performance for Q2 2025, driven by an improvement in inpatient volumes and higher revenue intensity across its key markets. IHH Group’s growth and transformation framework put in place since 2023 has allowed the Group to plan ahead and respond to structural shifts in care model from inpatient to daycare as we have anticipated and are already seeing in Singapore and Malaysia.

The Group is also further progressing on its transformation journey by embarking on a multi-year digital transformation journey modernizing platforms across our core markets by implementing C+ ERM in Singapore and India first followed by other countries.

We are also pleased to share that we have declared an interim dividend of 5 sens for FY2025, up from 4.5 sens last year and this is despite payor pressure and operational headwinds.

Dr Prem Kumar Nair
Group Chief Executive Officer, IHH Healthcare

GROUP RESULTS – FINANCIAL HIGHLIGHTS¹

Q2 2025 key metrics (Y-o-Y) change

Revenue	EBITDA	PATMI (ex EI)	PATMI
RM6.3b	RM1.4b	RM419m	RM443m
+3%	-	-4%	-29%

GROUP OPERATIONAL SUMMARY (FOR QUARTER ENDED 30 JUNE 2025)



Occupancy
(for Q2 2025)
68%



Inpatient Admissions
(for Q2 2025)
231,627 (+4%)



Lab Tests
(for Q2 2025)
27 million (+7%)

¹ The Group’s headline performance includes the application of the MFRS 129 accounting standard (Financial Reporting in Hyperinflationary Economies) relating to its entities in Türkiye.

Q2 2025: Healthy revenue growth, underpinned by strong operations


- Revenue increased 3% year-on-year while EBITDA was flat year-on-year. The growth in revenue was mainly attributed to increased contributions from Malaysia and Türkiye & Europe.
- On a constant currency basis, revenue grew 18% year-on-year and EBITDA increased 11% year-on-year, reflecting strong operational resilience.
- EBITDA contributions increased across most segments, offset by decreased EBITDA contributions from Singapore due to bed closures at Mount Elizabeth Hospital. Mount Elizabeth Hospital sees phased reopenings in July and early August and contribution from Mount Elizabeth Hospital will stabilise over the next two quarters by Q2 2026
- PATMI decreased 29% against last year mainly due to a lower net monetary gain from the application of MFRS 129, and the recognition of deferred tax credit last year arising from the revaluation of certain assets in Türkiye as allowed by the Türkiye government.
- We collaborated with regulators and payors and rolled out treatment packages for some specialties to address the challenge of increasing medical inflation costs.
- Our highly diversified healthcare portfolio, spanning multiple geographies, provides significant business resilience. This geographical spread allows us to buffer the impact of pressures in some countries with the strong performance of others, giving us a key strategic advantage.

H1 2025: Sustained core operational growth; strong financial position

- Revenue expanded 5% on sustained improvement in patient volumes and revenue intensity, while EBITDA was flat.
- Excluding exceptional items, PATMI (ex EI) was flat at RM844.0 million.
- Balance sheet remained strong: net cash generated from operating activities at RM2.5 billion; overall cash balance at RM1.5 billion.

GROUP OUTLOOK

IHH's 2025 strategic growth priorities :



- Amid rising healthcare demands domestically and across its key markets, the Group remains confident in its growth path.
- We have initiated a multi-year transformation plan to future-proof our business through continuous improvements and accelerate our growth priorities.
- The Group's transformation will be driven by seven focus areas - clinical excellence, patient experience, new care models, operational excellence, payor and regulator engagement, employee and doctor value proposition, and the advancement of technology, data, and artificial intelligence.
- The Group expects continued revenue growth driven by healthcare megatrends and will focus on driving profitability and sustaining healthy ROE while maintaining prudent capital management and mitigating inflationary and interest rate pressures.

+++

ABOUT IHH HEALTHCARE BERHAD (“IHH”)

A world-leading integrated healthcare provider, IHH believes that making a difference starts with our aspiration to Care. For Good.

Our team of more than 70,000 people commit to deliver greater good to our patients, people, the public and planet, as we live our purpose each day to touch lives and transform care.

Through our portfolio of trusted brands – Acibadem, Mount Elizabeth, Prince Court, Island Hospital, Gleneagles, Fortis, Pantai and Parkway – we offer our patients comprehensive and personalised care ranging from primary to quaternary, and even ancillary services such as laboratory, diagnostics, imaging and rehabilitation.

With a clear focus on clinical excellence and innovation, we continue to raise the bar in healthcare in our key markets of Malaysia, Singapore, Türkiye, India, Greater China (including Hong Kong) and beyond.

In partnership with our stakeholders, we will co-create a sustainable future for all as we work towards our vision to become the world’s most trusted healthcare services network.

More information can be found at www.ihhhealthcare.com.

+++

For more information or to speak to an IHH spokesperson, please contact:

Kelvin Chong
Investor Relations, IHH Healthcare
t. +65 9489 5357
e. kelvin.chong@ihhhealthcare.com

Joshua Kuek
Investor Relations, IHH Healthcare
t. +65 9675 3585
e. joshua.kuek@ihhhealthcare.com